Volumetric Modulated Arc Therapy After Lung Sparing Surgery for Malignant Pleural Mesothelioma: A Single Institution Experience.

Clinical Lung Cancer 2019 September 5 [Link] Franceschini D, De Rose F, Cozzi S, Renna I, Franzese C, Di Brina L, Navarria P, D’Agostino GR, Mancosu P, Tomatis S, Scorsetti M Abstract INTRODUCTION: We investigated the possible role of volumetric modulated arc therapy (VMAT) in the setting of adjuvant treatment of malignant pleural mesothelioma (MPM)…

Read More

Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy.

Oncotarget 2018 April 27 [Link] Mairinger FD, Schmeller J, Borchert S, Wessolly M, Mairinger E, Kollmeier J, Hager T, Mairinger T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Jasani B, Schmid KW, Bankfalvi A Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a biologically highly aggressive tumor arising from the pleura with a…

Read More

Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma

European Journal of of Radiology [2017 January] [Link] Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T Abstract PURPOSE: Efficient monitoring of tumor responsiveness to chemotherapy is essential to mitigate high mortality risks and cytotoxic effects of chemotherapeutics. However, there is no consensus on the most…

Read More

Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival

Clinical Epidemiology 2016 October [Link] Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, Gadgeel S Abstract INTRODUCTION: Mesothelioma is a rare malignancy typically associated with exposure to asbestos and poor survival. The purpose of this investigation was to describe mesothelioma patient characteristics, treatment patterns, and overall survival (OS) utilizing the National…

Read More

Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma

Journal of Clinical Oncology: Official journal of the American Society of Clinical Oncology 2016 June 20 [Epub ahead of print] [Link] Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC, Tsao AS, Rosenzweig KE, Rusch VW, Krug LM. Abstract PURPOSE: We conducted…

Read More

Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model

International Journal of Cancer 2016 June 10 [Epub ahead of print] [Link] Kuryk L, Haavisto E, Garofalo M, Capasso C, Hirvinen M, Pesonen S, Ranki T, Vassilev L, Cerullo V. Abstract Malignant mesothelioma (MM) is a rare cancer type caused mainly by asbestos exposure. The median overall survival time of a mesothelioma cancer patient is…

Read More

Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma

Medical Oncology 2015 February [Link] de Lima VA, Sorensen JB. Abstract There is no well-defined standard third-line chemotherapy for advanced malignant pleural mesothelioma (MPM). However, combination of carboplatin, liposomised doxorubicin (Caelyx) and gemcitabine (CCG regimen) has revealed noteworthy activity when used as first-line treatment. The aim of this study is to assess efficacy and toxicity…

Read More

Acute lower limb ischemia complicating pemetrexed and carboplatin combination chemotherapy for malignant pleural mesothelioma

Annals Italiani di Chirurgia 2014 November [Link] Valerio S, Bracale UM, Giribono AM, Viviani E, Caioni F, Del Guercio L. Abstract Pemetrexed and Carboplatin are two well-known chemioterapic agents used for the treatment of many tumors, especially for lung cancer and mesothelioma. Peripheral ischemic events related to Pemetrexed and Carboplatin are rarely reported. We herein…

Read More

Acute lower limb ischemia complicating pemetrexed and carboplatin combination chemotherapy for malignant pleural mesothelioma

Annali Italiani di Chirurgia 2014 November [Link] Valerio S, Bracale UM, Giribono AM, Viviani E, Caioni F, Del Guercio L. Abstract Pemetrexed and Carboplatin are two well-known chemioterapic agents used for the treatment of many tumors, especially for lung cancer and mesothelioma. Peripheral ischemic events related to Pemetrexed and Carboplatin are rarely reported. We herein…

Read More

Pemetrexed plus Carboplatin or Cisplatin as Neoadjuvant Treatment of Operable Malignant Pleural Mesothelioma (MPM)

Anticancer Research. 2012 Dec;32(12):5393-9. [Link] Pasello G, Marulli G, Polo V, Breda C, Bonanno L, Loreggian L, Rea F, Favaretto A. Via Gattamelata 64, 35128, Padua, Italy. giulia.pasello@ioveneto.it. Abstract Aim: The objective of this study was the retrospective evaluation of tolerability and activity of pemetrexed with carboplatin (AC) or cisplatin (AP) as neoadjuvant chemotherapy in…

Read More